Telehealth ADHD Prescribing: What Psychiatrists Can Do in Michigan

If you’re a psychiatrist or PMHNP considering telehealth ADHD care, you’ve probably searched some version of: ‘Can I legally prescribe Adderall through a video visit?’ or ‘What are the telehealth rules for stimulant prescriptions in 2026?’

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026 — but the regulatory landscape is complicated, state-dependent, and currently in flux. Let’s cut through the confusion.

Federal Telehealth Prescribing Rules: Where We Stand Now

Here’s what matters for your practice today:

The Ryan Haight Act (2008) originally required at least one in-person medical evaluation before prescribing Schedule II controlled substances like Adderall or Ritalin. During COVID, the DEA waived this requirement, allowing psychiatrists to initiate stimulant prescriptions entirely via telehealth.

Good news: In November 2024, the DEA and HHS extended these COVID-era flexibilities through December 31, 2025. This marked the third extension of the temporary telemedicine rules, giving providers another year of clarity.

The uncertainty: As of February 2026, we’re in limbo. Unless Congress passes permanent legislation or the DEA finalizes new rules, the in-person requirement could return. The DEA has floated proposals for a ‘special telemedicine registration’ that would allow controlled substance prescribing without initial face-to-face visits, but nothing concrete has been implemented.

What this means for you: Right now, you can conduct a thorough video evaluation of a new ADHD patient and e-prescribe stimulants without breaking federal law. But you should prepare contingency plans — partnering with local clinics for in-person exams, for instance — in case the rules tighten in late 2026 or 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Variations: It’s Not Just Federal Law

Even with federal allowances, state medical boards set their own telehealth standards. Some states have been explicitly welcoming to telepsychiatry for ADHD; others add layers of restriction.

The Most Provider-Friendly States

Florida explicitly permits telehealth prescribing of Schedule II stimulants for psychiatric disorders in its statutes. Florida carved out an exception to its general ban on tele-prescribing controlled substances, recognizing that mental health care is different from pain management. As a Florida-licensed psychiatrist, you can diagnose ADHD via video and prescribe Adderall without any state-level prohibition.

California follows federal guidance without adding extra barriers. CA mandates e-prescribing for all controlled substances (which telehealth platforms handle), but doesn’t require an in-person exam beyond what federal law says.

Illinois and New York similarly don’t impose state-specific telehealth restrictions on stimulant prescribing for psychiatrists. Both states have strong telehealth parity laws, meaning insurers pay you the same whether the visit is virtual or in-office.

States With Extra Considerations

Texas allows telehealth prescribing of controlled substances for mental health treatment via live video. However, Texas explicitly prohibits prescribing controlled substances for chronic pain through telemedicine alone. ADHD doesn’t fall under ‘chronic pain management,’ so psychiatrists can prescribe stimulants via video — just ensure you use synchronous audio-video (phone-only won’t cut it for controlled substances in Texas).

Pennsylvania doesn’t have a specific state law banning telehealth controlled-substance prescribing, but it also hasn’t passed comprehensive telehealth legislation. PA psychiatrists follow federal rules and the state medical board’s standard-of-care guidance. In practice, telepsychiatry for ADHD is common and accepted, but always document that you conducted a thorough evaluation equivalent to in-person care.

Psychiatrists vs PMHNPs: Who Can Prescribe What?

This is where scope of practice becomes critical — and it varies wildly by state.

Psychiatrists (MD/DO): You have unrestricted prescriptive authority in every state. You don’t need supervision, collaboration agreements, or special permissions to prescribe ADHD medications. The only limits you face are federal controlled-substance laws (DEA registration, PDMP checks) and standard-of-care requirements.

PMHNPs: Your ability to prescribe stimulants independently depends entirely on your state.

Full Practice Authority States (After Experience)

• New York: After 3,600 hours of supervised practice (~2 years), PMHNPs can practice and prescribe completely independently, including Schedule II stimulants. No ongoing physician oversight required.

• Illinois: After 4,000 hours of clinical practice plus 250 hours of additional training, PMHNPs can obtain Full Practice Authority. You’ll prescribe ADHD meds independently (no special consult requirement for stimulants, unlike the opioid rule).

• California: Transitioning to FPA. Experienced NPs (≥3 years, 4,600 hours) can now apply for independent ‘104 NP’ status. Until then, you need physician supervision. California requires PMHNPs to complete a controlled-substance pharmacology course to prescribe Schedule II drugs.

Restricted Practice States

• Texas: This is the strictest. Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings — period. Only exception: inpatient hospital, hospice, or emergency department. If you’re a PMHNP in Texas treating outpatient ADHD patients, you cannot write Adderall prescriptions. You’ll need a collaborating psychiatrist to handle all stimulant prescriptions. Texas is a huge market with severe psychiatry shortages, but NPs are legally sidelined from first-line ADHD medication management.

• Florida: PMHNPs must have a supervisory protocol with a psychiatrist. Florida generally limits NPs to 7-day supplies of Schedule II drugs — except Florida law explicitly exempts psychiatric nurses treating mental health conditions from this limit when working under a psychiatrist’s protocol. Translation: you can prescribe 30-day Adderall prescriptions for ADHD patients, but you’re not independent — you need that collaborative relationship with an MD.

• Pennsylvania: Requires physician collaboration for all NP practice. PA has a quirky rule: NPs can only prescribe a 72-hour initial supply of Schedule II drugs for new patients or conditions, then notify the supervising physician. Ongoing prescriptions can be 30-day supplies. In practice, many PA clinics have the psychiatrist write the first stimulant prescription, then the PMHNP handles monthly refills. It’s workable but adds procedural steps.

Bottom line: If you’re a psychiatrist, your license is your ticket to practice anywhere (with state licensure). If you’re a PMHNP, understand your state’s rules intimately — in some states you’re essentially equal to MDs for ADHD care; in others, you’re heavily restricted or dependent on physician oversight.

What a Compliant Telehealth ADHD Workflow Actually Looks Like

The scrutiny on telehealth ADHD prescribing has increased after high-profile cases of companies allegedly overprescribing stimulants with minimal evaluation. In 2023, investigations revealed some platforms were prescribing Adderall after brief messaging exchanges — raising serious safety and regulatory concerns.

As a legitimate provider, here’s how to ensure your practice meets both legal requirements and clinical standards:

Initial Evaluation

Conduct a comprehensive psychiatric evaluation via video. This should include:

• Detailed clinical interview (childhood history, current symptoms, functional impairment)
• Standardized ADHD rating scales (e.g., ASRS for adults, Vanderbilt for children)
• Ruling out other conditions (anxiety, depression, substance use)
• Collateral information when appropriate (school reports, partner observations)
• Mental status examination

Document everything. Your notes should demonstrate that the ADHD diagnosis meets DSM-5 criteria and that you assessed for contraindications and comorbidities.

Prescribing Protocol

• Verify patient identity and location at each visit (you need to know which state’s laws apply and confirm licensure)
• Check the PDMP before prescribing — most states require this for controlled substances. New York mandates a PDMP check for every controlled prescription; other states require it at least every 90 days.
• E-prescribe using DEA-compliant two-factor authentication (required federally for controlled substances)
• Coordinate any necessary in-person elements — baseline vital signs (blood pressure, heart rate), potentially an EKG in older adults or those with cardiac history. Many psychiatrists ask patients to get these from their PCP or use home monitoring.

Ongoing Management

Schedule regular follow-ups — typically monthly for stimulant prescriptions since Schedule II drugs can’t be refilled; each prescription is a new 30-day supply. Monitor:

• Symptom improvement and side effects
• Vital signs (patients can report home BP readings)
• Adherence and potential for misuse
• Functional outcomes (work, relationships, daily life)

This level of care isn’t just good medicine — it’s your protection if your prescribing ever faces review by a medical board or DEA.

The Economics: Is Telehealth ADHD Care Financially Viable?

Let’s talk money, because that’s what determines if you can build a sustainable practice.

Reimbursement Reality

By 2026, telehealth payment parity is nearly universal for mental health services. Medicare, Medicaid (in most states), and commercial insurers pay the same rate for virtual med checks as in-person visits.

Medicare rates for 2024-2025 (rates adjust annually but these are current ballpark figures):

• 99213 (15-min established patient visit): ~$89-95
• 99214 (25-min moderate complexity visit): ~$125-136
• 90792 (initial psychiatric evaluation with med management): ~$190-202

Commercial insurance typically pays equal to or 10-30% higher than Medicare for psychiatrists. Medicaid pays substantially less — often $40-65 for a med check in many states — but telehealth allows you to balance your payer mix.

Psychiatrists get paid at the highest tier for medication management compared to other provider types. Your MD/DO license means you bill E/M codes at physician rates, whereas NPs might get 85% of the physician fee schedule under some plans (though many platforms structure contracts to equalize this).

The Overhead Advantage

Telehealth ADHD medication management is one of the most economically efficient psychiatric services you can provide:

• No office rent or overhead — you work from home or a minimal office setup
• Minimal no-show rates — easier for patients to keep virtual appointments
• Higher visit volume — no commute time between patients; you can schedule four 15-minute med checks per hour
• Lower malpractice exposure than crisis or inpatient work

If you’re seeing Medicare patients at $90 per 15-minute visit and filling your schedule, that’s $360/hour gross revenue. With telehealth’s low overhead, your net income per hour can exceed traditional office-based psychiatry.

The Platform Model vs. Solo Practice

Many psychiatrists join telehealth platforms rather than building their own practice because patient acquisition is expensive and uncertain.

Reality check on DIY marketing costs:

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo psychiatrists don’t have the expertise or patience.
• Google Ads for mental health keywords run $15-40+ per click. A realistic cost per booked patient through PPC is $200-400+ after accounting for clicks that don’t convert, no-shows, and failed campaigns.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees plus per-booking fees, and you compete with hundreds of other providers on the same page.
• Total monthly marketing spend to reliably generate new ADHD patients: easily $3,000-5,000 with uncertain ROI when you factor in agency fees, staff time to qualify leads, and months of testing.

Platforms like Klarity Health use a pay-per-appointment model where you only pay when a qualified patient books with you. No upfront marketing spend, no monthly subscriptions, no wasted ad budget on clicks that don’t convert. The platform handles patient acquisition, matching, scheduling infrastructure, and billing — you just show up and provide care.

For most providers, especially those starting out or scaling from part-time to full-time telehealth, the platform model removes all financial risk from patient acquisition while guaranteeing you actually get paid for every patient you see.

Medication Shortages: The Hidden Practice Challenge

Since late 2022, ongoing Adderall and other stimulant shortages have frustrated both providers and patients. The DEA sets production quotas for controlled substances, and those quotas didn’t keep pace with surging demand during the pandemic (when adult ADHD diagnoses and treatment jumped significantly).

What this means for your practice:

• Frequent pharmacy stock-outs — patients call angry because their local CVS or Walgreens is out of their medication
• Formulary switching — you’ll need to be comfortable prescribing alternatives (Vyvanse, Concerta, Focalin, or non-stimulants like Strattera)
• Prior authorization headaches — insurance companies require PA for brand-name stimulants or non-preferred generics, adding unpaid administrative work
• Patient retention issues — some patients blame the provider when medications aren’t available, even though it’s a supply-chain problem

Provider tip: Build relationships with independent pharmacies in your telehealth service area. They often have better access to stimulant inventory than big chains. Also, become proficient with non-stimulant ADHD medications (atomoxetine, bupropion, guanfacine) as backup options — your patients will appreciate having alternatives when first-line meds are backordered.

State Market Realities: Where ADHD Providers Are Needed Most

High-Shortage States (Best Opportunities)

Texas: ~1 psychiatrist per 9,000 residents (rank 43rd nationally). Over 185 of 254 Texas counties are designated Mental Health Professional Shortage Areas. Huge demand, but remember: if you’re a PMHNP, you can’t prescribe stimulants for outpatient ADHD patients in Texas — only psychiatrists (MD/DO) can.

Florida: ~1 psychiatrist per 8,600 residents (rank 42nd). Strong demand especially in North Florida and interior regions. South Florida has more providers but still can’t keep up. Florida’s explicit telehealth-friendly law for psychiatric controlled substances makes this an attractive market.

Competitive But Undersupplied Markets

California: ~1 psychiatrist per 5,600 residents. Looks better on paper, but that’s skewed by high concentrations in San Francisco and LA. Central Valley, Inland Empire, and rural Northern California have severe shortages. Massive patient population means plenty of demand even with more providers.

Illinois: ~1 per 5,800 residents. Chicago is well-served; downstate Illinois needs providers desperately. Telehealth bridges this gap well.

Well-Served But High-Demand Markets

New York: ~1 per 2,900 residents (rank 4th nationally). NYC is saturated with psychiatrists, but upstate rural areas are shortage zones. High demand despite provider density because of population and growing awareness of adult ADHD.

Pennsylvania: ~1 per 4,600 residents (rank 10th). Philadelphia and Pittsburgh have adequate supply; rural PA struggles. Moderate competition but persistent access gaps telehealth can fill.

Staying Compliant: What Could Get You in Trouble

Given increased regulatory scrutiny, here are the red flags that draw attention:

❌ Prescribing after inadequate evaluations — 5-minute video chats don’t meet standard of care for initiating stimulants. Document comprehensive assessments.

❌ Ignoring PDMP red flags — If a patient is getting controlled substances from multiple providers or has a history of early refills, address it. Document your clinical decision-making.

❌ Not verifying patient location — You must know which state your patient is in (for licensure compliance) and document it.

❌ Audio-only visits for controlled substances in states requiring video — Texas and some others explicitly require video for controlled-substance prescribing.

❌ Prescribing outside your scope — PMHNPs in Texas writing Adderall scripts for outpatients, or NPs in any state prescribing without required collaborative agreements.

❌ Missing continuing education on controlled substances — Some states (California, Illinois) require specific training for NPs to prescribe Schedule II drugs. Stay current.

The providers who get disciplined are usually those who cut corners or run high-volume ‘prescribing mills.’ If you practice conscientiously — thorough evaluations, proper documentation, regular follow-ups, coordinating with other providers when needed — you’re in the clear.

FAQ: ADHD Telehealth Prescribing for Providers

Can I prescribe stimulants to a patient in a different state than where I’m licensed?

No. You must hold an active medical license in the state where the patient is physically located at the time of the telehealth visit. Multi-state practice requires multi-state licensure (or using interstate compacts where available, though psychiatry doesn’t have a universal compact yet).

Do I need a separate DEA registration for telehealth prescribing?

No. Your existing DEA registration covers telehealth prescribing of controlled substances. You just need to comply with federal telemedicine rules (currently the extended COVID flexibility, or future DEA telemedicine registration if implemented). You do need a DEA registration in each state where you practice, though.

How often do I need to check the Prescription Drug Monitoring Program?

This varies by state. New York requires checking before every controlled-substance prescription. Many states require checking at least once before initiating therapy and then periodically (often every 90 days) for ongoing treatment. Check your state medical board’s specific rules.

Can I prescribe 90-day supplies of ADHD medications to reduce visit frequency?

Federal law prohibits refills on Schedule II medications. However, you can write multiple prescriptions for sequential 30-day supplies (e.g., three separate scripts for 30 days each, dated for future fills). Some states restrict this or have quantity limits. Most telehealth ADHD practices stick to monthly visits and prescriptions to maintain close monitoring.

What if my patient’s insurance requires prior authorization for their ADHD medication?

Prior authorizations are a reality of psychiatric prescribing. Most telehealth platforms have staff to handle PA paperwork, but as the prescriber, you may need to provide clinical justification. Starting with generic medications (generic Adderall, methylphenidate) usually avoids PA. Brand-name drugs like Vyvanse almost always trigger PA.

Am I liable if my telehealth patient diverts or misuses their medication?

You have the same standard of care and liability as in-person practice. Document your evaluation, monitoring, and any concerns. If you discover misuse, address it clinically (decrease dose, switch to non-stimulant, discontinue, refer to addiction treatment). Following clinical guidelines and documenting appropriately provides significant liability protection.

Can I provide both therapy and medication management in the same telehealth visit?

Yes. You can bill both psychotherapy and medication management using add-on codes (e.g., 99214 + 90833 for a combined visit). However, most telehealth ADHD medication-management practices focus on brief med checks (15-25 minutes) rather than full therapy sessions, simply for time efficiency and revenue optimization.

The Bottom Line: Should You Practice Telehealth ADHD Care?

If you’re a psychiatrist (MD/DO), telehealth ADHD medication management is one of the most straightforward, financially stable, and clinically rewarding niches in psychiatry right now:

✅ High demand nationwide with severe provider shortages in many states
✅ Strong reimbursement with universal payer coverage for telehealth
✅ Low overhead and high scheduling efficiency
✅ Clear clinical protocols — ADHD is well-defined with evidence-based treatment
✅ Regulatory clarity (for now) — extended federal rules through 2025, with most states supportive

Challenges to prepare for:

• Regulatory uncertainty in 2026+ if federal rules change
• Medication shortages requiring flexibility with prescribing
• Heightened scrutiny requiring thorough documentation

If you’re a PMHNP, your opportunity depends entirely on your state:

• Full practice states (NY, IL, CA eventually): You can build an independent ADHD telehealth practice comparable to an MD, especially after meeting experience requirements.

• Restricted states (TX, FL, PA): You’ll need physician collaboration, and in Texas you’re essentially blocked from stimulant prescribing for outpatients. Focus on non-stimulant ADHD treatment, therapy, or team up with a psychiatrist who handles the controlled substances.

Next Step: Join a Platform That Handles the Hard Parts

If you’re ready to start or scale your telehealth ADHD practice, the biggest barrier isn’t clinical — it’s patient acquisition and operational infrastructure.

Klarity Health provides both:

For Providers:

• Qualified patient flow — we handle all marketing, patient matching, and scheduling. You only pay when a patient books.
• No upfront costs — no monthly fees, no marketing gambles, no wasted ad spend. Pay-per-appointment model.
• Both insurance and cash-pay patients — diversified revenue with full billing support.
• Built-in telehealth platform — HIPAA-compliant video, e-prescribing, documentation, all integrated.
• You control your schedule — set your availability, see patients on your terms.

Why this matters economically: Instead of spending $3,000-5,000/month on marketing with uncertain ROI (or 6-12 months building SEO with zero patients initially), you get guaranteed patient flow from day one and only pay when you’re actually earning.

For multi-state providers: Klarity operates in multiple states, so if you’re licensed in several, you can serve patients across your licensed jurisdictions through one platform.

Explore Klarity Health’s provider network → (Platform handles credentialing, contracting, and compliance — you focus on medicine)

Sources and References

The information in this guide is based on current federal and state regulations, industry data, and healthcare policy analysis as of February 2026. Key sources include:

Federal and State Law:

1. Florida Statutes §456.47 (Telehealth – controlled substances exceptions for psychiatric disorders) – Florida Senate, 2023 session. www.flsenate.gov

2. Florida Statutes §464.012 (APRN prescribing authority and psychiatric nurse exception to 7-day limit) – Florida Legislature, 2025 edition. www.leg.state.fl.us

3. Texas Senate Bill 2527 Analysis (88th Legislature) – Discussion of telehealth controlled-substance prescribing standards and abuse concerns. Texas Legislature, April 2023. capitol.texas.gov

4. Center for Connected Health Policy (CCHP) – ‘Texas State Telehealth Laws and Reimbursement Policies.’ Updated January 19, 2026. www.cchpca.org/texas

5. RxAgent – ‘Nurse Practitioner Prescriptive Authority by State: 2026 Comprehensive Guide’ (PharmD-authored analysis of NP scope of practice and controlled-substance prescribing by state). Updated December 28, 2025. rxagent.co/blog/np-prescribing-authority

Federal Policy and Healthcare News:

6. Axios – ‘COVID-era telehealth prescribing for controlled substances extended through 2025’ (DEA/HHS third extension announcement). November 18, 2024. www.axios.com

7. Axios – ‘Telehealth prescribing mess could reach Congress this fall’ (Analysis of impending expiration of Ryan Haight Act waivers). September 18, 2024. www.axios.com

8. Axios – ‘DEA ramps up production limits for ADHD medications’ (Report on DEA increasing manufacturing quotas due to shortages). September 5, 2024. www.axios.com

Clinical and Market Data:

9. Associated Press – ‘More adults sought ADHD help during the pandemic, driving medication shortages’ (Analysis of prescription surge and FDA data). January 10, 2024. apnews.com

10. Healing Psychiatry Florida – ‘Psychiatrist Shortage by State: 2026 Report’ (State-by-state psychiatrist-to-population ratios compiled from HRSA data). January 15, 2026. www.healingpsychiatryflorida.com/blogs/psychiatrist-shortage-by-state

Reimbursement and Practice Economics:

11. Therathink – ‘Insurance Reimbursement Rates for Psychiatrists [2026 Update]’ (Medicare, Medicaid, and commercial payer rates for psychiatric CPT codes). Updated 2026. therathink.com/insurance-reimbursement-rates-for-psychiatrists

12. BehaveHealth – ‘Mental Health Reimbursement Trends: Telehealth Parity in 2026’ (Industry analysis of payment parity across states). 2024. behavehealth.com/mental-health-reimbursement-2024

13. Kiplinger – ‘Medicare Telehealth Benefits Expanded Through 2025’ (Summary of Medicare telehealth coverage extensions). Updated 2025. www.kiplinger.com/retirement/medicare/medicare-telehealth-expanded-in-2025

All sources accessed and verified February 2026. Official statutes and regulations reflect the most current available versions. Healthcare policy sources dated 2023-2026 reflect the evolving regulatory environment for telehealth controlled-substance prescribing.

This content is for informational purposes and does not constitute legal or medical advice. Providers should verify current regulations with their state medical board and DEA, and consult legal counsel for specific compliance questions.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the